NVUS - ト―カイ・ファ―マシュ―ティカルズ (Novus Therapeutics Inc.)

NVUSのニュース

   Novus Therapeutics Appoints June Lee, M.D., to Board of Directors  2020/12/09 13:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company’s Board of Directors.
   Israel Gp Ltd. Orbimed Sells 103,200 Shares of Novus Therapeutics, Inc. (NASDAQ:NVUS) Stock  2020/12/06 09:46:49 Watchlist News
Novus Therapeutics, Inc. (NASDAQ:NVUS) major shareholder Israel Gp Ltd. Orbimed sold 103,200 shares of the company’s stock in a transaction dated Wednesday, December 2nd. The shares were sold at an average price of $21.60, for a total value of $2,229,120.00. The sale was disclosed in a filing with the SEC, which is available at this […]
   Zacks: Analysts Anticipate Novus Therapeutics, Inc. (NASDAQ:NVUS) to Post -$1.64 EPS  2020/11/16 17:23:30 Transcript Daily
Wall Street brokerages expect Novus Therapeutics, Inc. (NASDAQ:NVUS) to report earnings of ($1.64) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Novus Therapeutics’ earnings. Novus Therapeutics reported earnings of ($3.96) per share in the same quarter last year, which indicates a positive year over year growth rate of 58.6%. […]
   Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16  2020/11/10 22:04:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corpo
   Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis  2020/11/02 13:00:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
   Novus Therapeutics Appoints June Lee, M.D., to Board of Directors  2020/12/09 13:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company’s Board of Directors.
   Israel Gp Ltd. Orbimed Sells 103,200 Shares of Novus Therapeutics, Inc. (NASDAQ:NVUS) Stock  2020/12/06 09:46:49 Watchlist News
Novus Therapeutics, Inc. (NASDAQ:NVUS) major shareholder Israel Gp Ltd. Orbimed sold 103,200 shares of the company’s stock in a transaction dated Wednesday, December 2nd. The shares were sold at an average price of $21.60, for a total value of $2,229,120.00. The sale was disclosed in a filing with the SEC, which is available at this […]
   Zacks: Analysts Anticipate Novus Therapeutics, Inc. (NASDAQ:NVUS) to Post -$1.64 EPS  2020/11/16 17:23:30 Transcript Daily
Wall Street brokerages expect Novus Therapeutics, Inc. (NASDAQ:NVUS) to report earnings of ($1.64) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Novus Therapeutics’ earnings. Novus Therapeutics reported earnings of ($3.96) per share in the same quarter last year, which indicates a positive year over year growth rate of 58.6%. […]
   Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16  2020/11/10 22:04:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corpo
   Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis  2020/11/02 13:00:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
   Novus Therapeutics Appoints June Lee, M.D., to Board of Directors  2020/12/09 13:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company’s Board of Directors.
   Israel Gp Ltd. Orbimed Sells 103,200 Shares of Novus Therapeutics, Inc. (NASDAQ:NVUS) Stock  2020/12/06 09:46:49 Watchlist News
Novus Therapeutics, Inc. (NASDAQ:NVUS) major shareholder Israel Gp Ltd. Orbimed sold 103,200 shares of the company’s stock in a transaction dated Wednesday, December 2nd. The shares were sold at an average price of $21.60, for a total value of $2,229,120.00. The sale was disclosed in a filing with the SEC, which is available at this […]
   Zacks: Analysts Anticipate Novus Therapeutics, Inc. (NASDAQ:NVUS) to Post -$1.64 EPS  2020/11/16 17:23:30 Transcript Daily
Wall Street brokerages expect Novus Therapeutics, Inc. (NASDAQ:NVUS) to report earnings of ($1.64) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Novus Therapeutics’ earnings. Novus Therapeutics reported earnings of ($3.96) per share in the same quarter last year, which indicates a positive year over year growth rate of 58.6%. […]
   Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16  2020/11/10 22:04:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corpo
   Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis  2020/11/02 13:00:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

calendar